Background: CyberKnife ® (CK) is a new, advanced radiotherapy technique. This study aimed to
Introduction
Lung cancer is one of the most prevalent cancers and is a leading cause of death in Japan and worldwide. Lung cancers are being detected increasingly early because of the widespread use of computed tomography (CT). For patients with early-stage non-small cell lung cancer (NSCLC), surgical resection is the treatment choice that promises high local control and survival rates (1) . However, some patients are not considered eligible for surgical resection because of co-morbidities such as poor respiratory function, poor cardiac function or advanced age.
For such patients, radiotherapy can be a therapeutic alternative. Although historical 5-year survival rates using conventional radiotherapy for patients with early-stage NSCLC are only 5-30% (2-4), stereotactic body radiotherapy (SBRT) has recently been reported as being highly effective (5) (6) (7) (8) (9) . SBRT in lung cancer is a modern technique that allows the delivery of a higher dose to the target while decreasing irradiation to the surrounding healthy tissue. Although randomized Phase III clinical trials with the aim of comparing SBRT with surgery on operable patients closed early due to slow accrual (10) , SBRT is now widely used in clinical practice for patients with earlystage NSCLC who are medically unfit for curative surgery. However, the applicability of SBRT using the conventional technique has been limited due to difficulties in targeting tumors that move with breathing, particularly those located in the lower lobe and/or peripheral area.
The CyberKnife ® (CK) system (Accuray Incorporated, Sunnyvale, CA, USA) was first described in 1997 (11) , with Whyte et al. subsequently reporting its feasibility and safety in NSCLC (12) . CK uses a new and advanced technology that allows for SBRT by delivering radiotherapy from multiple angles with real-time target tracking. Several methods of real-time tracking are currently available. For example, the fiducial tracking system requires the use of fiducial markers placed near or within the tumor (13) (14) (15) , whereas the Xsight ® Spine or Lung Tracking System (16) is fiducial-free, with radiation delivered to the tumor within a predetermined margin. These tracking techniques are accurate to within 1.5 mm, allowing correct planning treatment volume margins. Such tracking methods provide the precise targeting of the tumor and maximal sparing of healthy lung tissues, providing major advantages over SBRT based on linear accelerators. There has been increasing clinical research from outside Japan on the efficacy of CK treatment (12) (13) (14) (15) (16) , but as yet, there has been no report from Japan. This study aimed to evaluate the efficacy and toxicity of CK treatment in Japanese patients at a single institution.
Patients and methods

Eligibility criteria
We retrospectively assessed all consecutive patients who received CK treatment at the Japanese Red Cross Medical Center, Tokyo, Japan between June 2011 and September 2016. All enrolled patients satisfied the following eligibility criteria: primary lung tumor identified as T1aN0M0, T1bN0M0 or T2aN0M0 according to the 7th edition of the American Joint Committee on Cancer (AJCC) staging system assessed from chest and abdomen CT scans, 18 F-fluoro-deoxy-glucose positron emission tomography (FDG-PET), and brain magnetic resonance imaging; tumor diameter of ≤50 mm; World Health Organization performance status score of ≤3; medical inoperability due to poor medical conditions; and histologically confirmed NSCLC. If histological proof could not be obtained, patients were included when the lesion was considered a malignancy, i.e. it was observed to be increasing in size on serial CT scan and exhibiting FDG update on PET scans (17) . Patients with any lung infectious disease or inflammatory disease were not enrolled in this study. Patients with metastatic and recurrent lesions were excluded. Metastatic lung tumor was ruled out by FDG-PET, brain magnetic resonance imaging and/or gastrointestinal endoscopy. Not all patients underwent gastrointestinal endoscopy. However, FDG uptake on PET scan in the gastrointestinal tract was seen in none of the patients. Finally, 40 patients were included.
Treatment methods
A summary of the treatment method is given in Table 1 . CK version 9.6.0.2 and CK Treatment Planning System version 4.6.0 were used. Quality assurance of dose and beam accuracy was performed every day. A CT scan with 1-mm slices was performed, and the gross tumor volume (GTV) delineated on CT images was displayed with a window level of −300 Hounsfield units (HU) and a window width of 1700 HU. The dose was calculated using Monte Carlo simulation. A total of 36-48 gray (Gy) (median, 43 Gy) was administered to each patient in 4-5 fractions. The radiation dose was changed depending on the location of the tumor; accordingly, the dose to central lesions was reduced by 20%.
Two kinds of guidance systems were used onboard the CK platform: the Synchrony Respiratory Motion Tracking System (n = 28), which used fiducial markers placed in or near the tumor using a bronchoscope to synchronize beam delivery with the motion of the target resulting from respiration, and the Xsight Spine Tracking System (n = 12), which used the bony anatomy of the spine to locate and track the tumors. Four-dimensional CT was performed before CK treatment to determine which of two guidance systems was more preferable. If the respiratory movement of the tumor was >10 mm, Synchrony Respiratory Motion Tracking System was chosen. Otherwise, the Xsight Spine Tracking System was adopted for guidance. A geometrical 3-5-mm margin at the Synchrony Respiratory Motion Tracking System and 3-mm margin at the Xsight Spine Tracking System were added to the GTV according to four-dimensional CT to create the planning target volume. An example treatment plan with fiducial markers is shown in Fig. 1 . A biologically effective dose (BED) was used based on a linearquadratic model (18) . BED 10 was defined as nd [1 + d/(α/β)], in units of Gy, where n and d represent the number of fractions and the fraction size, respectively, and α/β is assumed to be 10 Gy for tumors. The median BED was 89.3 (range, 68.4-105.6) Gy. No restriction was placed on whether the tumor was peripherally or centrally located in the lung.
Follow-up and evaluation
The patients were followed-up by both respiratory physicians and radiation oncologists. Chest and abdomen CT scans were usually performed every 2-3 months in the first year and repeated every 4-6 months thereafter. The tumor response was evaluated by CT according to the Response Evaluation Criteria in Solid Tumors (19) . Local control was calculated from the time of treatment until tumor relapse. It was often difficult to distinguish between a viable tumor and secondary changes, including radiation pneumonitis (RP) and fibrosis. Local recurrence was defined only by the continued enlargement of the primary tumor on follow-up CT, a viable tumor was histologically confirmed, or positive findings were obtained on performing FDG-PET. In line with a previous report (20) , a cutoff of 5 or higher of standardized uptake value on performing FDG-PET was adopted to determine malignancy. In each patient, CT and FDG-PET findings were interpreted by one respiratory physician and two radiation oncologists. Toxicity was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Follow-up duration was defined as the period from the day of treatment completion to the day of the final follow-up or death. The date of follow-up termination was 30 September 2016.
Statistical analysis
The statistical objectives included evaluations of the local progression-free survival rate, disease-free survival rate, overall survival rate, and the RP incidence rate. The survival rates were calculated and drawn using Kaplan-Meier algorithms. Median time to the events was estimated along with a 95% confidence interval (CI).
For the local progression-free survival rate, the event was defined as local recurrence alone, whereas for the disease-free survival rate, the event was defined as local disease, regional lymph node, or distant site recurrence. Both rates were censored at the time of death or loss to follow-up. Time until recurrence was calculated from the date of treatment completion to either the date of the event or the date of censoring. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). CK treatment and were diagnosed with a second cancer. The median follow-up was 14.5 (range, 1-51) months. No patient was lost to the follow-up evaluation.
Ethics statement
Local control and survival
A summary of survival and outcomes is shown in Table 3 . During the observation period, local recurrence occurred in seven (17.5%) patients. The tumor locations were as follows: right upper lobe, n = 2; right lower lobe, n = 1; left upper lobe, n = 2; and left lower lobe, n = 2. The median tumor diameter was 22 (range, 17-50) mm. The time to local recurrence varied between 5 and 40 months. At 1 year, 83.9% [95% CI: 62.0-93.7] of the patients maintained local control. However, 74.0% (95% CI: 50.5-87.6) of the patients achieved local control by 2 year, although the median time to local progression of disease was never achieved ( Fig. 2A) . Overall, 16 patients developed disease progression during the follow-up period. Nine (22.5%) patients experienced distant recurrence as the initial progression occurring in regional lymph nodes (n = 5) at distant sites (n = 4); in the lung outside of the radiation field (n = 3) and in the bone (n = 1) ( Table 3 ). The disease-free survival rates at 1 and 2 years were 64.4% (95% CI: 43.2-79.3) and 50.8% (95% CI: 30.0-68.4), respectively (Fig. 2B) .
Seven patients died during follow-up. The survival time from CK treatment varied from 3 to 51 months. Six patients died from the progression of lung cancer and one from RP. Overall survival rates at 1 and 2 years were 93.6% (95% CI: 76.5-98.4) and 73.1% (95% CI: 48.6-87.3), respectively (Fig. 2C) .
Toxicity
RP was identified in 28 of the 40 patients. The cumulative rate of RP is shown in Fig. 3 . The median time to the development of RP was 4 (range, 3-8) months. There was no correlation between chronic lung diseases and RP development. Twenty-five patients developed Grade 1 RP, but this resolved without steroid therapy. However, Grade 2 RP was identified in two patients who needed steroid therapy. The tumor was located in the right lower lobe in one patient and in the left lower lobe in the other; both patients received 48 Gy in four fractions (BED, 105.6 Gy 10 ). Grade 5 RP was observed in one patient who died of an acute exacerbation of interstitial pneumonia after CK treatment. She was diagnosed with usual interstitial pneumonia by transbronchial lung biopsy in 1999. Although pirfenidone and prednisolone were started in 2010, the pulmonary function gradually declined and lung involvement progressed from lower lobes to upper lobes. In February 2012, CT showed an 18-mm nodule in the left upper lobe. She was diagnosed with NSCLC, not otherwise specified by transbronchial biopsy (clinical stage T1aN0M0). She was judged as medically inoperable due to poor respiratory function and received a radiation dose of 48 Gy in four fractions (BED 105.6 Gy 10 ). RP occurred 3 months after CK treatment, and she died after 2 weeks despite treatment with highdose steroids.
As of the last examination, no vascular, cardiac, esophageal, skin or bone marrow complications were encountered, and no radiation-induced rib fracture or pneumothorax was identified. There was no technical complication during fiducial placement, including pneumothorax and bleeding. The fiducials sometimes fell or moved; however, CK treatment was accurately performed using the remaining fiducials.
Discussion
In this study, medically inoperable patients with early-stage primary lung tumor were treated with CK to a range of BEDs of 68.4-105.6 Gy 10 . The local control rate at 1 year (83.9%) and overall survival rate at 1 year (93.6%) and 2 years (73.1%) were excellent. Although the incidence of RP was high (70%), most patients recovered without steroid treatment.
Previous reports on the efficacy of CK treatment described 1-and 2-year local control rates of 81.8-93.2% and 86-96%, respectively (16, (21) (22) (23) . In those studies, overall survival rates at 1 and 2 years was 85.5-93.6% and 79.4-87%, respectively (16, (21) (22) (23) . In our study, the local control rate at 1 year and overall survival rate at 1 and 2 years were comparable to those of these studies. Local recurrence occurred in seven patients irrespective of the tumor location; this showed that good local control was expected even for tumors located in the lower lobes, which would be considered difficult for targeting by SBRT using the conventional technique. However, the local control rate at 2 years was 74.0%, which was lower than the rates described in previous reports. A possible reason for this is the BED. In our study, most patients received 48 Gy in four fractions (BED, 105.6 Gy 10 ), in line with a previous study (8) . However, the prescribed radiation dose was changed depending on the location of the tumor; accordingly, the dose to central lesions was reduced by 20%. Furthermore, several reports have described different effects of SBRT depending on the radiation dose. For example, van der Voort van Zyp et al. reported a trend toward an improved local control rate with a higher radiation dose, with a 2-year local control rate of 96% in patients treated with 60 Gy compared with a rate of 78% in those treated with 45 Gy (P = 0.197) (24) . Another study described better overall survival with BED ≥ 132 Gy 10 than with BED ≤ 132 Gy 10 (P = 0.01) (23) . Considering these results, the radiation dose in our study may be relatively low and thus possibly related to the lower local control rate at 2 years. Because CK showed limited toxicity, the radiation dose could have been increased. In this study, most patients died from the progression of lung tumor and no patient died from intercurrent disease. A possible reason for this was the relatively low local control rate. Although the exact reason is unknown, this result suggested proper patient selection in this study. Further research is needed to determine whether the local control rate improves with dose escalation and which patients are eligible for such escalation. The toxicities associated with CK in our study were generally mild. However, one of the five patients with radiological features of pulmonary fibrosis developed Grade 5 RP 3 months after CK treatment. Several studies have reported patients with pulmonary fibrosis developing Grade 4-5 RP after SBRT (25) (26) (27) (28) , including when using CK treatment (23) . In particular, Bahig et al. reported that three of five patients (60%) with pulmonary fibrosis developed Grade 5 RP (23). Although pulmonary fibrosis is not a contraindication to SBRT, the risk of severe RP or acute exacerbation of interstitial pneumonia should be considered. Better predictive markers of RP are needed. For tracking, we used both fiducial tracking and the Xsight Spine Tracking System. There was no technical complication during the fiducial placement in this study, probably because fluoroscopic guidance was used. However, pneumothorax and other complications are often observed during this procedure (15, 29, 30) . Past studies have shown no significant difference in survival outcome and tumor control rates between the fiducial and Xsight tracking systems (22) . Thus, the fiducial-free tracking system appears to be a safe and effective alternative technique.
This study has several limitations. First, this was a retrospective study without pre-planned criteria of clinical effectiveness. Larger prospective trials and longer follow-up durations are needed to evaluate the efficacy and safety of CK treatment. Second, the number of patients was small, and the follow-up duration was insufficient. Third, some patients received CK treatment without pathological confirmation. This is often the case in SBRT studies for lung cancer (24) . To minimize this limitation, we used serial CT images and FDG uptake on performing PET.
In conclusion, CK treatment provided good local control in Japanese patients with primary lung tumor, irrespective of the tumor location. CK can therefore be considered as an alternative treatment modality for medically inoperable patients with Stage І primary lung Figure 2 . Local progression-free survival rate (A), disease-free survival rate (B), and overall survival rate (C).
tumor. In general, toxicities were minimal, but patients with pulmonary fibrosis may be at greater risk of severe RP. Particular attention should therefore be given to patients with pulmonary fibrosis.
